BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025 ...
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...
CAMBRIDGE, Mass. and HOUSTON, April 9, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a ...
By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...
Island Pharmaceuticals’ March quarterly update highlights considerable progress advancing the clinical development pathway ...
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...
Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...
Headshot of Sumit Chanda standing outside Scripps Research Institute. Sumit Chanda has dedicated his career to antiviral drug research. Credit: Courtesy of the Chanda Lab The US National Institutes of ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results